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I.  Introduction 
 Since the first description of CXCL8/interleukin-8 (IL-8) as a 
neutrophil chemotactic cytokine in 1987, a family of structurally related 
cytokines has been identified. Because most of them exhibit chemotactic activity 
against a limited spectrum of leukocytes, they are now called chemokines 
(chemotactic cytokines). Chemokines direct the movement of various types of 
cells, particularly leukocytes, along concentration gradient, by modulating 
expression and structure of adhesion molecules and cytoskeletal proteins of the 
target cells. Due to their molecular stability and target specificity, chemokines 
are presumed to be crucial in leukocyte infiltration and subsequent activation in 
inflammation. Moreover, chemokines participate in other various biological 
phenomena including immune reactions, angiogenesis, and organ development. 
 Chemokines are divided into four subgroups, CXC, CC, C, and CX3C 
(Table 1). CXC, CC, and CX3C chemokines have four cysteines, whereas C 
chemokines have only two, corresponding to the second and fourth cysteines in 
the other groups. CXC and CX3C chemokines are distinguished by the presence 
of one (CXC) and three amino acids (CX3C), while the first two cysteines are 
adjacent in CC chemokines. Chemokines exhibit 3-β  sheets with α helix at the 
carboxyl terminal portion, due to the presence of two disulfide bridges formed 
between the first and the third, and between the second and the fourth cysteines. 
CXCL16 and CX3CL1 are expressed in a membrane-bound form but other 
chemokines are secreted proteins with a molecular weight about 10 kDa. They 
exhibit a basic nature and their α helix structure is responsible for preferential 
binding to proteoglycans on the vascular endothelial cells and to extracellular 
matrix proteins. Chemokine receptors comprise a large branch of the rhodopsin 
family of cell-surface G-protein-coupled receptors (GPCR) with 
seven-transmembrane domains. Functional binding to the target cells and 
subsequent signaling is mediated by these receptors.  
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A nomenclature system has been proposed for chemokines and their 
receptors. Systematic chemokine names, shown in Table 1 with their common 
names, are built from cysteine subclass roots, followed by “L” for “ligand”. The 
numbers correspond generally to the same number used in the corresponding gene 
nomenclature. Because most chemokine receptors are restricted to a single 
chemokine subclass, the nomenclature system of chemokine receptors is rooted by 
the chemokine subclass specificity, followed by “R” for “receptor” and the 
number (Table 2). 
 
II.  Chemokine receptors and their signal transduction mechanism 
Until present, approximately 20 chemokine receptors have been identified 
(Table 2). Chemokine receptors are a G-protein coupled receptor (GPCR) with 7 
transmembrane portions and are coupled with heterotrimeric Gαβγ proteins bound 
to intracellular loops (Figure 1). The Gα subunit contains a GTPase domain 
involved in binding and hydrolysis of GTP. In the inactive state, the Gα subunit 
binds GDP, and interacts directly with the intracellular loop of chemokine 
receptors and with Gβ  subunit, which in turn forms a tight complex with Gγ  
subunit. A chemokine specifically recognizes and binds the receptor. 
Consequently, the amino-terminus of the chemokine interacts with the receptor, 
leading to the activation of receptor. Simultaneously, ligand binding induces 
internalization of the chemokine receptor by using the clarthrin-mediated 
pathway or the lipid rafts/caveole-dependent internalization routes. Internalized 
receptors are recycled and reappear on the cell surface quickly. 
 The ligand binding activates pertussis toxin-sensitive and 
receptor-coupled G-proteins, particularly Gαi proteins. G-proteins, upon 
conversion to the guanosine triphosphate (GTP)-bound form, dissociate into Gα 
and Gβγ subunits. Generated Gβγ activates phosphatidylinositol 4-phoshate 
kinase (PIP-K), phosphpolipase C (PLC)-β,  and phosphosphatidyl-3-kinase-γ 
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(PI3Kγ). PIP-K and PLC-β  generate inositol 1,4,5-trisphosphate (IP 3 ) and diacyl 
glycerol (DAG). IP 3  induces transient increase in intracellular Ca 2+  through 
mobilization of intracellular Ca 2+  store while DAG activates protein kinase C. 
These steps are required for superoxide production and granule release but not 
chemotaxis. The activation of PI3Kγ leads to the generation of PIP 3 .  PIP 3 , in 
turn, activates protein kinase B (Akt) and small GTPases, resulting in chemotaxis 
and adherence. In addition, active Gα and Gβγ facilitate the polarization of the 
cells with the leading edge (pseudopodium) in the front and the formation of a 
trailing tail (uropod) at the back. PI3K and Rac accumulate at the leading edge to 
induce actin polymerization and F-actin formation. Simultaneously, Rho and its 
effector molecules accumulate at the trailing edge to facilitate actomyosin 
contraction and tail retraction, thereby leading to the migration of the cells. PIP 3  
also activates Raf and mitogen-activated protein kinase (MAPK) pathway, leading 
to the transcription of various genes. 
 GPCR-mediated signals can be down-regulated by RGS (regulator of 
G-protein signaling) proteins. RGS proteins appear to enhance the endogenous 
GTPase activities and thus decrease the half-life of the active GTP-bound state of 
both trimeric G-proteins and small GTPases. RGS1, RGS3, and RGS4 reduce 
CXCL8-mediated migration and adherence together with attenuated 
CXCL8-induced MAPK activation. 
The binding of a chemokine to its corresponding receptor expose the 
tyrosine residue in DRY motif in the second transmembrane region. This exposure 
allows access of Janus kinase, which activates the receptor by tyrosine 
phosphorylation. Simultaneous activation of Janus kinase leads to the recruitment 
of STAT (signal transducers and activators of transcription) and eventually 
STAT-mediated expression of the target genes (Figure 1). Moreover, this pathway 
requires ligand-induced homodimerization of chemokine receptors, as observed 
on other GPCRs that can frequently exist as dimers and/or high-order oligomers. 
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III. Chemokines in leukocyte trafficking and functions 
Chemokines are functionally designated as homeostatic and inflammatory 
chemokines. Homeostatic chemokines are constitutively expressed and control 
basal leukocyte trafficking, such as lymphocyte homing to secondary lymphoid 
organs. On the contrary, the inflammatory chemokines are expressed in response 
to infection and tissue injury, and are responsible for the recruitment of effector 
leukocytes to the site of inflammation. Some chemokines exert both homeostatic 
and inflammatory funcitons. Representative inflammatory chemokines are CXC 
chemokines, which bind CXCR1 and/or CXCR2 and possess a 3-amino acid 
sequence, glutamic acid-leucine-arginine (the “ELR” motif), immediately 
preceding the CXC sequence. Human ELR-motif-positive CXC chemokine genes 
are present in cluster at chromosome 4q13.3. These chemokines regulate 
cooperatively neutrophil infiltration observed in acute inflammation. Another 
major inflammatory chemokine is CCL2, which have a crucial role in 
monocyte/macrophage infiltration in chronic inflammation. Moreover, 
CCR3-binding CC chemokines, particularly CCL11, CCL24, and CCL26, are 
major regulators of eosinophil infiltration. 
Immune response consists of two phases; innate and adaptive immunity.  
Innate immune response is mediated by natural killer (NK) cells in addition to 
neutrophils and monocytes. NK cells migrate to lymph nodes mainly by utilizing 
CXCR3 and CCR7, while their migration to the inflamed tissues including tumor 
sites involves CCR1, CCR2, CCR5, CXCR3, and CX3CR1. Thus, the ligands for 
these receptors can regulate NK cell trafficking and augment their functions. 
Adaptive immunity is mediated by the interaction between 
antigen-presenting cells and T and B lymphocytes. Dendritic cells (DCs) are 
professional antigen-presenting cells and widely distributed over peripheral 
tissues. DCs in peripheral tissues are in an immature state with a high capacity to 
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endocytose various materials and express various chemokine receptors including 
CCR1, CCR2, CCR4, CCR5, CCR6, CCR8, and CXCR4. The ligands for these 
receptors can attract immature DCs, which capture exogenous and endogenous 
antigens. When DCs capture antigens in the presence of inflammatory stimuli, 
they change to a mature state with a loss of endocytosis ability and start to 
migrate into the T cell areas of regional lymph nodes via afferent lymphatic 
venules under the guidance of CCR7. Mature DCs process the antigens into the 
peptides presented on MHC molecules, exhibit enhanced expression of 
co-stimulatory molecules, and induce primary immune responses through antigen 
presentation to T cells in the regional lymph node. 
In addition to mature DCs, the ligands for CCR7, CCL19 and CCL21, 
induce the migration of naïve T and B lymphocytes towards the T cell zone of the 
secondary lymphoid organs. Moreover, CXCL13 induce B cell homing to follicle 
of the lymph node under homeostatic conditions. In the lymph nodes, DCs present 
antigen to T lymphocytes to make them effector cells. T lymphocytes are 
polarized into various typrs of effector cells including cytotoxic T lymphocytes,  
Th1, Th2, and regulatory T cells. Effector T lymphocytes express distinct sets of 
chemokine receptors (Table 2) and migrate to the periphery in response to the 
corresponding chemokine to conduct their functions. 
 
IV. Chemokines and non-leukocytic cells 
Neovascularization is crucial for tissue repair at inflammatory responses 
and tumor growth. ELR motif-positive CXC chemokines, CXCL1, CXCL2, 
CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 can directly promote the 
migration and proliferation of endothelial cells and eventually neovascularization, 
mainly interacting with CXCR2 but not CXCR1. CXCL12 is not an ELR-positive 
CXC chemokine but exhibits potent angiogenic effects. In addition, three CC 
chemokines, CCL2, CCL11, and CCL16 have also been implicated in tumor 
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neovascularization. Moreover, CCL2 can indirectly induce tumor 
neovascularization by recruiting tumor-associated macropahges, which can 
produce various angiogenic factors and can be incorporated into tumor 
vasculature. On the contrary, CXCL4 and interferon-inducible ELR 
motif-negative CXC chemokines such as CXCL9, CXCL10, and CXCL11 inhibit 
the angiogenesis and after binding a common receptor, CXCR3. 
Chemokines have direct impacts on tumor cells. Oncogene-induced 
senescence (OIS) serves as a potent barrier against oncogenic transformation by 
suppressing the unscheduled proliferation of early neoplastic cells. The cells 
undergoing OIS secrete CXCR2-binding chemokines and IL-6 through the 
activation of 2 pro-inflammatory transcription factors, C/EBP-β  and NF-κB. The 
secreted CXCR2-binding chemokines can promote the arrest of cellular growth 
and eventually delay the early phase of tumorigenesis. On the contrary,  
pro-tumorigenic gene expression and proliferation in tumor cells can be enhanced 
by various chemokines including CXCL8, CXCL12, CXCL16, CCL19, CCL20, 
CCL21, CCL27, and CCL28. Moreover, CXCL8 and CXCL12 have an important 
role in epithelial-mesenchymal transition (EMT), a crucial step for tumor 
invasion and metastasis. CXCL12 and CCL21 can further confer the survival 
advantage on tumor cells circulating in bloodstream. Furthermore, CXCR4, CCR7, 
CCR9, CXCR1, and CXCR2 are detected in tumor cells and their ligands can 
induce the chemotaxis of the corresponding receptor-expressing cells. As a 
consequence, specific chemokine receptor-expressing tumor cells can migrate to 
and survive in the organs with high expression levels of respective chemokines. 
Thus, chemokines may accelerate metastasis by promoting tumor cell 
proliferation or preventing tumor cell death. 
These findings collectively suggest that chemokines can prevent 
tumorigenesis in the early phase by inducing cellular senescence and can also 
Mukaida 8 
promote invasion and metastasis in the later phase by enhancing the motility and 
survival of tumor cells. 
 
V. Chemokines and virus infection 
 CCR5 and CXCR4 have been described as major co-receptors of human 
immunodeficiency virus (HIV)-1 entry.  Viruses capable of exploiting CCR5 
(R5-trpoic) are predominant during the asymptomatic phase of HIV infection, 
whereas viruses found in late-stage use preferentially CXCR4 as their co-receptor. 
Non-silent CXCR4 polymorphism has been identified but is not associated with 
progression to AIDS. The ∆32 mutation in the CCR5 gene leads to the production 
of a truncated CCR5, due to a premature stop codon arising from a 32 bp deletion 
in the gene sequence. Individuals homozygous for the CCR5∆32 (1 % of 
Caucasians) do not express CCR5 at the cell surface and therefore are resistant to 
the infection by R5-tropic HIV strains. The CCR5-m303A mutation also 
introduces a premature stop codon and confers resistance to HIV infection in 
vitro. Other chemokine rececptors, CCR2, CXCR6, and CX3CR1, can be utilized 
by several HIV strains. 
 Human cytomegalovirus, a β-herpesvirus, encodes two CXC chemokine 
homologs, UL146 and UL147 and one CC chemokine homolog, UL128. 
Cytomegalovirus further encodes four chemokine receptor homologs, US28, US27, 
UL33, and UL78, and one chemokine scavenging protein, UL21.5.  These virus 
gene products are presumed to have an important role in the life cycle of 
cytomegalovirus. Among γ-herpesvirus, Epstein-Barr virus encodes one 
chemokine receptor homolog while Kaposi sarcoma-associated herpes virus 
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Chemokine name Other names for human chemokines  Chromosome     Main receptors 
CXC 
CXCL1  groα, melanoma growth stimulating activity (MGSA) 4q13.3  CXCR2 
CXCL2  groβ     4q13.3  CXCR2 
CXCL3  groγ     4q13.3  CXCR2 
CXCL4  platelet factor 4 (PF4)    4q13.3  CXCR3 
CXCL5  endothelial derived neutrophil attractatant-78 (ENA-78) 4q13.3  CXCR2 
CXCL6  granulocyte chemotactic protein-2 (GCP-2)  4q13.3  CXCR1, CXCR2 
CXCL7  neutrophil activating protein-2 (NAP-2)  4q13.3  CXCR2 
CXCL8  interleukin-8 (IL-8)    4q13.3  CXCR1, CXCR2 
CXCL9  monokine induced by interferon γ (Mig)  4q21.1  CXCR3 
CXCL10  interferon-inducible protein-10 (IP-10)  4q21.1  CXCR3 
CXCL11  interferon-inducible T cell α chemoattractant (I-TAC) 4q21.1  CXCR3, CXCR7 
CXCL12  stromal cell-derived factor-1 (SDF-1)α/β  10q11.21  CXCR4, CXCR7 
CXCL13  B-lymphocyte chemoattractant (BLC)  4q21.1  CXCR5 
CXCL14  breast and kidney (BRAK)   5q31.1  unknown 
CXCL15  unidentified in human 
CXCL16  SR-PSOX     17p13.2  CXCR6 
CXCL17  DMC     19q13.2  unknown 
CC 
CCL1  I-309     17q11.2  CCR8 
CCL2  monocyte chemoattractant protein (MCP)-1  17q11.2  CCR2 
CCL3  macrophage inflammatory protein (MIP)-1α, LD78α 17q11.2  CCR1, CCR5 
CCL3L1  MIP-1αP, LD78β    17q12  CCR1, CCR3, CCR5 
CCL4  MIP-1β, small inducible cytokine A4  17q12  CCR5 
CCL4L1  small inducible cytokine A4-like 1   17q12  CCR5 
CCL5  RANTES     17q12  CCR5, CCR1, CCR3 
CCL6  unidentified in human 
CCL7  MCP-3     17q11.2  CCR1, CCR2, CCR3 
CCL8  MCP-2     17q11.2     CCR1, CCR2, CCR3, CCR5 
CCL9  unidentified in human 
CCL10  unidentified in human 
CCL11  eotaxin     17q11.2  CCR3, CCR5 
CCL12  unidentified in human 
CCL13  MCP-4     17q11.2     CCR1, CCR2, CCR3, CCR5 
CCL14  human hemofiltrae CC chemokine (HCC)-1  17q12  CCR1 
CCL15  HCC-2     17q12  CCR1, CCR3 
CCL16  HCC-4     17q12  CCR1, CCR2, CCR5 
CCL17  thymus and activation-regulated chemokine (TARC) 16q13  CCR4 
CCL18  pulmonary and activation-regulated chemokine (PARC) 17q12  unknown 
CCL19  EBI1-ligand chemokine (ELC), MIP-3β  9p13.3  CCR7  
CCL20  MIP-3α, LARC    2q36.3  CCR6 
CCL21  secondary lymphoid-tissue chemokine (SLC), 6Ckine 9p13.3  CCR7 
CCL22  macrophage-derived chemokine (MDC)  16q13  CCR4 
CCL23  myeloid progenitor inhibitory factor (MPIF)-1  17q12  CCR1 
CCL24  eotaxin-2, MPIF-2    7q11.23  CCR3 
CCL25  thymus-expressed chemokine (TECK)  19p13.2  CCR9 
CCL26  eotaxin-3     7q11.23  CCR3 
CCL27  interleukin-11 receptor α-locus chemokine (ILC) 9p13.3  CCR10 
CCL28  mucosae-associated epithelial chemokine (MEC) 5p12  CCR10, CCR3 
CX3C 
CX3CL1  fractalkine     16q13  CX3CR1 
C 
XCL1  lymphotactin, single cysteine motif (SCM)-1α  1q24.2  XCR1 
XCL2  SCM-1β     1q24.2  XCR1 
 
Table 1. Human hemokines and their corresponding receptors 
Receptor    Chemokines     Receptor expression in 
     Leukocytes     Epithelium   Endothelium Fibroblast 
CXC 
CXCR1 CXCL6, 8              PMN   + - - 
CXCR2 CXCL1, 2, 3, 5, 6, 7, 8   PMN   + + - 
CXCR3 CXCL4, 9, 10, 11   Th1, NK   - + - 
CXCR4 CXCL12    Widespread  + + - 
CXCR5 CXCL13    B   - - - 
CXCR6 CXCL16                        activated T   + - + 
CXCR7 CXCL11, CXCL12                Widespread  + + - 
      CC 
CCR1 CCL3, 3L1, 5, 7, 8, 13, 14, 15, 16, 23     Mo, Mφ, iDC, NK  + + - 
CCR2 CCL2, 7, 8, 13, 16                  Mo, Mφ, iDC, NK, activated T, B + + - 
CCR3 CCL5, 7, 8, 11, 13, 15, 24, 26, 28  Eo, Ba, Th2  - + - 
CCR4 CCL17, 22                   iDC, Treg, Th2, NK, T, Mφ - - -  
CCR5 CCL3, 3L1, 4, 4L1, 5, 8, 11, 13, 16 Mo, Mφ, NK, Th1, activated T + - + 
CCR6 CCL20    iDC, activated T, B  + - - 
CCR7 CCL19, 21    mDC, Mφ, naïve T, activated T + - - 
CCR8 CCL1    Mo, iDC, Th2, Treg  - - - 
CCR9 CCL25    T   + - - 
CCR10 CCL27, 28    activated T, Treg  + - - 
       CX3C 
CX3CR1 CX3CL1                      Mo, iDC, NK, Th1  + - - 
       XC 
XCR1 XCL1, 2    T, NK, DC   - - - 
 
 
Table 2. The human chemokine system. Leukocyte anonyms are as follows: Ba, basophil; Eo, eosinophil; iDC, 
immature dendritic cell; mDC, mature dendritic cell; Mo, monocyte; Mφ, macrophage; NK, natural killer cell; PMN, 
polymorphonuclear cell; Th1, type I helper T cell; Th2, type II helper T cell; Treg, regulatory T cell. 
 
Chemokine receptors 

































Figure.  Major signaling pathways of chemokines 
